Detalhe da pesquisa
1.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622840
2.
Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma.
Value Health
; 26(6): 909-917, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738785
3.
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
J Oncol Pharm Pract
; 29(5): 1172-1177, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36067063
4.
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Am J Hematol
; 97(4): 481-490, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089607
5.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
6.
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Br J Haematol
; 194(1): 132-139, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822368
7.
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.
Br J Haematol
; 193(3): 561-569, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33555030
8.
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
BMC Cancer
; 21(1): 659, 2021 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34078314
9.
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Ann Hematol
; 100(4): 1065-1077, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33599794
10.
Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple Myeloma.
Value Health
; 24(12): 1807-1819, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838279
11.
Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss.
Qual Life Res
; 28(6): 1641-1653, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796591
12.
MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: a critical assessment.
Pharmacoepidemiol Drug Saf
; 26(12): 1483-1491, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28696023
13.
Preferences for Prostate Cancer Outcomes: A Comparison of the Patient Perspective, the General Population Perspective, and a Population at Risk for Prostate Cancer.
Value Health
; 19(2): 218-25, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27021756
14.
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Clin Lymphoma Myeloma Leuk
; 24(3): 194-202, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052709
15.
Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis.
Qual Life Res
; 22(10): 2801-8, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23645458
16.
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Clin Lymphoma Myeloma Leuk
; 23(1): 68-77, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36357295
17.
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies.
Cancer Rep (Hoboken)
; 5(11): e1603, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35168299
18.
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Lancet Haematol
; 9(12): e897-e905, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36215989
19.
Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany.
Patient
; 14(5): 613-623, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33686594
20.
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
J Cancer Res Clin Oncol
; 147(2): 619-631, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852632